Alkermes price target raised to $37 from $36 at Mizuho

Mizuho analyst Uy Ear raised the firm’s price target on Alkermes to $37 from $36 and keeps a Buy rating on the shares. The analyst expects "solid" Q1 results and says Alkermes remains a top pick. The firm continues to see potential upside from a Vivitrol patent settlement, Lybalvi, low pipeline expectations, and value creation from the planned oncology spin-off.